Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer.

BACKGROUND We designed a prospective study to test epidermal growth factor receptor (EGFR) expression by immunohistochemistry (IHC) in resected stage I-IIIA non-small-cell lung cancer (NSCLC) and to correlate overexpression with survival. PATIENTS AND METHODS EGFR expression was evaluated in 130 consecutive NSCLC patients after radical surgery (60 squamous cell carcinomas, 48 adenocarcinomas, 22 large cell carcinomas: stage I, 41 (31%); stage II, 37 (29%) and stage IIIA, 52 (40%). RESULTS Overall, 101 of 130 (78%) specimens expressed EGFR, and with a cut-off value of 10% positive cells 48 cases (37%) were classified as positive. At univariate analysis, EGFR was significantly more expressed in stage III (50%) than stage I (20%) and stage II (25%) (P <0.03). No correlation with histotype was found. After a median follow-up of 84 months, both median survival time (18 versus 50 months), 2-year (43% versus 70%) and 5-year (31% versus 46%) survival rates of positive cases were significantly lower than negative ones [P <0.001; hazard ratio 1.96; 95% confidence interval (CI) 1.16-3.30]. At the multivariate analysis, EGFR overexpression and stage emerged as independent factors for cancer-related mortality. CONCLUSION In patients with radically resected stage I-IIIA NSCLC, EGFR overexpression predicts shorter survival, thus representing a valuable prognostic factor.

[1]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[2]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[3]  V. Torri,et al.  HER‐2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma , 2002, Cancer.

[4]  E. Dmitrovsky,et al.  Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. , 1993, Cancer research.

[5]  K. Pavelić,et al.  Evidence for a role of EGF receptor in the progression of human lung carcinoma. , 1993, Anticancer research.

[6]  John Mendelsohn,et al.  The EGF receptor family as targets for cancer therapy , 2000, Oncogene.

[7]  M. Volm,et al.  Prognostic significance of the expression of c-fos, c-jun and c-erbB-1 oncogene products in human squamous cell lung carcinomas , 2005, Journal of Cancer Research and Clinical Oncology.

[8]  B. Ozanne,et al.  Human squamous cell lung cancers express increased epidermal growth factor receptors. , 1984, The Journal of clinical investigation.

[9]  C. Rose,et al.  Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. , 1996, British Journal of Cancer.

[10]  V. Gorgoulis,et al.  Expression of EGF, TGF-alpha and EGFR in squamous cell lung carcinomas. , 1992, Anticancer research.

[11]  Ahmedin Jemal,et al.  Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.

[12]  R. Nicholson,et al.  EGFR and cancer prognosis. , 2001, European journal of cancer.

[13]  A. Hölscher,et al.  Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  O. Auerbach.  Histological Typing Of Lung Tumors , 1968 .

[15]  C. Angeletti,et al.  Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  C. Arteaga.  The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  K. O'Byrne,et al.  Herceptest: Her2 expression and gene amplification in non‐small cell lung cancer , 2001, International journal of cancer.

[18]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[19]  Y. Yarden,et al.  Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. , 2000, Advances in cancer research.

[20]  K. O'Byrne,et al.  Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  M Paesmans,et al.  The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis , 2002, European Respiratory Journal.

[22]  H. Poulsen,et al.  Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  G Milano,et al.  Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (‘Iressa’) , 2002, British Journal of Cancer.

[24]  K. Kikuchi,et al.  Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. , 2000, Oncology reports.

[25]  Y. Shimosato,et al.  Histological Typing of Lung Tumours 1 , 1981 .

[26]  N. Reinmuth,et al.  Ploidy, expression of erbB1, erbB2, P53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer. , 2000, The European respiratory journal.

[27]  C. Angeletti,et al.  Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. , 1995, European journal of cancer.

[28]  G. Tortora,et al.  A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  E. Dmitrovsky,et al.  Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  D. Heimburger,et al.  Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  C. Mountain,et al.  A new international staging system for lung cancer. , 1987, Chest.

[32]  M. Buyse,et al.  Immunocytochemical markers in stage I lung cancer: relevance to prognosis. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  D. Bigner,et al.  Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. , 1993, Cancer research.

[34]  G. Gibson,et al.  Epidermal growth factor receptors in non-small cell lung cancer. , 1987, British Journal of Cancer.

[35]  M. Kris,et al.  Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  A. Harris,et al.  Towards a biological staging model for operable non-small cell lung cancer. , 2001, Lung cancer.

[37]  F. Hirsch,et al.  Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas , 2002, British Journal of Cancer.